Immune effector cells expressing extracellular pd-l1 binding domain car and linked to secreted interferon fusion proteins and methods of use thereof

By expressing an extracellular PD-L1 binding domain and a secretory interferon fusion protein in PD1-CAR-T cells, the problem of unstable treatment effects caused by fluctuations in PD-L1 expression in tumor cells was solved, achieving sustained activation of T cell function and efficient killing of tumor cells.

CN122404571APending Publication Date: 2026-07-17SHENZHEN RUIKE HAOKANG MEDICAL TECH CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202610487955.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-14
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Existing immunotherapy strategies that rely on PD-1/PD-L1 blockade are difficult to stabilize and continuously relieve T cell suppression when PD-L1 expression in tumor cells fluctuates dynamically, leading to limited treatment efficacy or drug resistance.

Method used

A chimeric antigen receptor (CAR) expressing an extracellular PD-L1 binding domain and binding to a secretory interferon fusion protein was designed to enhance the killing power of T cells against tumor cells. By expressing fusion proteins such as IFN or IFN-IL-2 in PD1-CAR-T cells, tumor cells were stimulated to increase PD-L1 expression to enhance killing power.

Benefits of technology

Under the condition of fluctuating PD-L1 expression in tumor cells under external stimulation, T cell function is continuously activated, which enhances the killing and inhibitory effects on tumor cells and strengthens the persistence and effectiveness of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122404571A_ABST
    Figure CN122404571A_ABST
Patent Text Reader

Abstract

The present application discloses immune effector cells expressing extracellular PD-L1 binding domain CAR and linking secretory interferon fusion protein and application methods thereof. The protein construct involved in the immune effector cells includes: (a) a chimeric antigen receptor (CAR) containing a PD-L1 binding domain; and (b) a secretory fusion protein containing IFN. The protein construct stimulates tumor cells to increase the expression amount or frequency of PD-L1, thereby further enhancing the killing ability of PD1-CAR-T cells on target cells and more effectively inhibiting or killing tumor cells.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Antigenic peptides based on histone H3 K27M mutant peptide and their applications

    CN112646020B

  • Optimized antigen peptide aiming at L858R point mutation of EGFR exon 21 region and application thereof

    CN119306792A

  • Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors

    WO2010089782A1